US FDA declines Moderna flu vaccine review amid vaccine guidance rollback
February 11, 2026
CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.
February 11, 2026
CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.